ARTICLE | Company News
Amgen, Novartis biosimilars news
June 29, 2015 7:00 AM UTC
The Sandoz unit of Novartis requested that the U.S. Court of Appeals for the Federal Circuit (CAFC) post a bond or lift its injunction barring Sandoz from launching Zarxio filgrastim-sndz. Zarxio is a biosimilar of Neupogen filgrastim, a recombinant methionyl human G-CSF from Amgen. In May, Sandoz requested a $179.4 million bond from Amgen to compensate for losses due to Zarxio’s delayed launch. Sandoz’s letter to the CAFC said Amgen did not contest the bond proposal (see BioCentury, May 18). ...